B和T淋巴细胞衰减蛋白抗体

B和T淋巴细胞衰减蛋白抗体 Background: B and T lymphocyte attenuator (BTLA), an immunoglobulin domain-containing glycoprotein with two immunoreceptor tyrosine-based inhibitory motifs. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. Crosslinking BTLA with antigen receptors induces its tyrosine phosphorylation and association with the Src homology domain 2 (SH2)-containing protein tyrosine phosphatases SHP-1 and SHP-2, and attenuates production of interleukin 2 (IL-2). BTLA-deficient T cells show increased proliferation, and BTLA-deficient mice have increased specific antibody responses and enhanced sensitivity to experimental autoimmune encephalomyelitis. B7x, a peripheral homolog of B7, is a ligand of BTLA. Thus, BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1). Also known as: B and T lymphocyte associated protein; B and T lymphocyte attenuator; B and T lymphocyte associated; BTLA; BTLA1; CD272 antigen; FLJ16065; MGC129743; BTLA_HUMAN; B- and T-lymphocyte attenuator; B- and T-lymphocyte-associated protein; CD272.B和T淋巴细胞衰减蛋白抗体